Protagenic Therapeutics (PTIX) Stock Price, News & Analysis

Company Overview

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $3.08 to $3.87
• 50-Day Range: $2.73 to $5.85
• 52-Week Range: $2.35 to $26.18
• Volume: 741,248 shs
• Average Volume: 122,990 shs
• Market Capitalization: $28.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Protagenic Therapeutics Stock Analysis - MarketRank™

Protagenic Therapeutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 903rd out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Protagenic Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Protagenic Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protagenic Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protagenic Therapeutics has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.53% of the float of Protagenic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagenic Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protagenic Therapeutics has recently increased by 319.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protagenic Therapeutics does not currently pay a dividend.

Dividend Growth

Protagenic Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.53% of the float of Protagenic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagenic Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protagenic Therapeutics has recently increased by 319.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Protagenic Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for PTIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Protagenic Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.00% of the stock of Protagenic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.97% of the stock of Protagenic Therapeutics is held by institutions.

PTIX Stock Analysis - Frequently Asked Questions

How have PTIX shares performed this year?

Protagenic Therapeutics' stock was trading at $6.86 at the beginning of the year. Since then, PTIX stock has decreased by 48.9% and is now trading at $3.5050.
View the best growth stocks for 2025 here.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) issued its earnings results on Monday, March, 31st. The company reported ($3.36) EPS for the quarter.

When did Protagenic Therapeutics' stock split?

Protagenic Therapeutics's stock reverse split on the morning of Monday, May 5th 2025. A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protagenic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Processa Pharmaceuticals (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 5/08/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTIX
• CIK: 1022899
• Web: www.protagenic.com
• Phone: 212-994-8200
• Fax: 603-761-6223
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,000,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -308.97%
• Return on Assets: -228.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.80
• Quick Ratio: 1.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 4.22

Miscellaneous

• Outstanding Shares: 8,243,000
• Free Float: 4,707,000
• Market Cap: $28.85 million
• Optionable: Not Optionable
• Beta: 0.28